Showing results (171-180 of 210) with videos related to

Sort By:
Pageof 21
Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.
The Lancet. Haematology|May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trialMeletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
European Journal of Haematology|September 8, 2021
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsPaul G Richardson, Fredrik Schjesvold, Katja Weisel, et al.
Leukemia|February 27, 2025
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomesThierry Facon, Philippe Moreau, Katja Weisel, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Future Oncology (London, England)|March 8, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study designAjay K Nooka, Katja Weisel, Niels Wcj van de Donk, et al.
Blood|December 14, 2011
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben, Henk M Lokhorst, Anna Jauch, et al.
Advances in Therapy|February 24, 2024
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple MyelomaHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood|September 22, 2025
Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 studyAjai Chari, Niels W C J van de Donk, Bhagirathbhai Dholaria, et al.
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Pageof 21